Phase II Study of Intraperitoneal Cisplatin Plus Systemic Etoposide as Second-line Treatment in Patients With Small Volume Residual Ovarian Cancer

Author： de Jong R.S.   Willemse P.H.B.   Boonstra H.   de Vries E.G.E.   van der Graaf W.T.A.   Sleijfer D.T.   van der Zee A.G.J.   Mulder N.H.  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.31, Iss.5, 1995-01, pp. : 709-713

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a phase II study

By Seto Takashi   Takezako Yoriko   Nakamura Hiroko   Takeda Kayo   Inoue Fumiko   Semba Hiroshi   Eguchi Kenji  

International Journal of Clinical Oncology, Vol. 9, Iss. 5, 2004-10 ,pp. : 378-382

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Trial of High-Dose Cisplatin Plus Ifosfamide as First-Line Followed by Carboplatin as Second-Line Treatment in Epithelial Ovarian Carcinoma

By Strauss G.   Lund B.   Hansen M.   Hansen H.H.  

Gynecologic Oncology, Vol. 66, Iss. 1, 1997-07 ,pp. : 66-70

Elsevier

Access to resources Recommend Favorite

Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabinerefractory pancreatic cancer patients

By                                  

Oncology Letters, Vol. 3, Iss. 6, 2012-01 ,pp. : 1314-1318

Spandidos Publications

Access to resources Recommend Favorite

A Phase II Trial of Intraperitoneal Cisplatin and Etoposide as Consolidation Therapy in Patients with Stage II-IV Epithelial Ovarian Cancer Following Negative Surgical Assessment

By Barakat R.R.   Almadrones L.   Venkatraman E.S.   Aghajanian C.   Brown C.   Shapiro F.   Curtin J.P.   Spriggs D.  

Gynecologic Oncology, Vol. 69, Iss. 1, 1998-04 ,pp. : 17-22

Elsevier

Access to resources Recommend Favorite

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG0803)

By Wu Y.-L.   Zhou C.   Cheng Y.   Lu S.   Chen G.-Y.   Huang C.   Huang Y.-S.   Yan H.-H.   Ren S.   Liu Y.   Yang J.-J.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 993-999

Oxford University Press

Access to resources Recommend Favorite